Substituted spirobenzazepines
    1.
    发明授权
    Substituted spirobenzazepines 有权
    取代的螺苯并氮平

    公开(公告)号:US07687494B2

    公开(公告)日:2010-03-30

    申请号:US11735149

    申请日:2007-04-13

    IPC分类号: A61P9/00 A61K31/55 C07D223/32

    CPC分类号: C07C205/57 C07D223/32

    摘要: The invention is directed to nonpeptide substituted benzazepines of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension, among others disclosed. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

    摘要翻译: 本发明涉及式I的非肽取代的苯并氮杂,其可用作加压素受体拮抗剂,用于治疗与加压素受体活性相关的病症,例如涉及增加的血管阻力和心功能不全的那些,包括充血性心力衰竭,低钠血症和高血压等 披露 包含式I化合物的药物组合物和治疗诸如高血压,充血性心力衰竭,心脏功能不全,冠状动脉血管痉挛,心脏缺血,肝硬化,低钠血症,肾血管痉挛,肾衰竭,糖尿病性肾病,脑水肿,脑缺血, 中风,血栓形成或保水性也被公开。